FDA
-
-
-
-
-
-
-
Fractyl Health names Mike Zumdahl senior VP of market access
-
-
-
-
-
-
-
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
-
-
-
-
-
-
-
Fractyl Health reports weight loss results from obesity gene therapy
-
-
-
-
-
-
-
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
-
-
-
-
-
-
-
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type
-
-
-
-
-
-
-
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek®
-
328,347 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

